Showing 2661-2670 of 7413 results for "".
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- Study: Brepocitinib Reduces Inflammatory Markers in Cicatricial Alopeciahttps://practicaldermatology.com/news/study-brepocitinib-reduces-inflammatory-markers-in-cicatricial-alopecia/2471712/A recent phase 2a clinical trial showed brepocitinib was associated with a significant reduction in C-C motif chemokine ligand 5 (CCL5) expression and improved clinical severity scores in patients with cicatricial alopecia (CA).
- Meta-Analysis Validates SLNB Prediction Toolshttps://practicaldermatology.com/news/meta-analysis-validates-slnb-prediction-tools/2471653/A new systematic review and meta-analysis found several externally validated risk prediction models for sentinel lymph node biopsy (SLNB) positivity in melanoma with strong discriminative performance, though significant heterogeneity was observed.
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- Treating Hyperpigmented/Hypertrophic Scars with Microneedling in Skin of Colorhttps://practicaldermatology.com/news/Treating-Hyperpigmented-Hypertrophic-Scars-Microneedling-Skin-Color/2471641/Robyn Siperstein, MD, FAAD, presented “Use of Microneedling in Skin of Color: Treating Hyperpigmented and Hypertrophic Scars” at the 2025 American Academy of Dermatology Annual Meeting Sunday. “The key to this treatment and how I’ve really changed my anti-aging treatments are two things: O
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Research Letter: Molecule Enhances Skin Barrier, Reduces Retinoid Side Effectshttps://practicaldermatology.com/news/research-letter-molecule-enhances-skin-barrier-reduces-retinoid-side-effects/2471610/A formulation containing Epicutis Skincare’s proprietary TSC molecule significantly reduced erythema and dryness caused by tretinoin, according to a research letter published in the Journal of Cosmetic Dermatology.
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- New Spesolimab Data Indicate Impact on Both Physical, Mental Healthhttps://practicaldermatology.com/news/New-Spesolimab-Data-Indicate-Impact-Both-Physical-Mental-Health/2471581/New analyses of the effects of spesolimab on the physical symptoms and mental health burden associated with generalized pustular psoriasis (GPP) were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. These post-hoc exploratory analyses from the